scholarly journals Efficacy and Safety of Clarithromycin, Lenalidomide and Dexamethasone (Bird) Therapy for Japanese Patients with Relapsed or Refractory Multiple Myeloma

2019 ◽  
Vol 3 (1) ◽  
pp. 4-8
Author(s):  
Hitoshi Hanamoto ◽  
◽  
Aki Fujii ◽  
Mariko Fujita ◽  
Ko Fujimoto ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Refractory Multiple Myeloma

MM-169: ANCHOR (OP-104): Melflufen Plus Dexamethasone and Bortezomib in Relapsed/Refractory Multiple Myeloma (RRMM)—Optimal Dose, Updated Efficacy and Safety Results

2021 ◽  
Vol 21 ◽  
pp. S425-S426
Author(s):  
Roman Hájek ◽  
Luděk Pour ◽  
Miquel Granell ◽  
Vladimir Maisnar ◽  
Paul G Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Optimal Dose ◽  
Efficacy And Safety ◽  
Refractory Multiple Myeloma

scholarly journals PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 251
Author(s):  
K. Weisel ◽  
A. Spencer ◽  
S. Lentzsch ◽  
H. Avet-Loiseau ◽  
T.M. Mark ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Subgroup Analysis ◽  
Efficacy And Safety ◽  
Refractory Multiple Myeloma

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

Blood ◽  
2008 ◽  
Vol 112 (12) ◽  
pp. 4445-4451 ◽  
Author(s):  
Michael Wang ◽  
Meletios A. Dimopoulos ◽  
Christine Chen ◽  
M. Teresa Cibeira ◽  
Michel Attal ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Overall Response Rate ◽  
Response Rate ◽  
Progression Free Survival ◽  
Efficacy And Safety ◽  
Time To Progression ◽  
Free Survival ◽  
Refractory Multiple Myeloma ◽  
Previously Treated ◽  
Survival Studies

AbstractThis analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide. Of 704 patients, 39% were thalidomide exposed. Thalidomide-exposed patients had more prior lines of therapy and longer duration of myeloma than thalidomide-naive patients. Lenalidomide + dexamethasone led to higher overall response rate (ORR), longer time to progression (TTP), and progression-free survival (PFS) versus placebo + dexamethasone despite prior thalidomide exposure. Among lenalidomide + dexamethasone-treated patients, ORR was higher in thalidomide-naive versus thalidomide-exposed patients (P = .04), with longer median TTP (P = .04) and PFS (P = .02). Likewise for dexamethasone alone-treated patients (P = .03 for ORR, P = .03 for TTP, P = .06 for PFS). Prior thalidomide did not affect survival in lenalidomide + dexamethasone-treated patients (36.1 vs 33.3 months, P > .05). Thalidomide-naive and thalidomide-exposed patients had similar toxicities. Lenalidomide + dexamethasone resulted in higher rates of venous thromboembolism, myelosuppression, and infections versus placebo + dexamethasone, independent of prior thalidomide exposure. Lenalido-mide + dexamethasone was superior to placebo + dexamethasone, independent of prior thalidomide exposure. Although prior thalidomide may have contributed to inferior TTP and PFS compared with thalidomide-naive patients, these parameters remained superior compared with placebo + dexamethasone; similar benefits compared with placebo + dexamethasone were not evident for thalidomide-exposed patients in terms of overall survival. Studies were registered at http://www.clinicaltrials.gov under NCT00056160 and NCT00424047.

scholarly journals S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 739 ◽  
Author(s):  
P.G. Richardson ◽  
A. Oriol ◽  
A. Larocca ◽  
P. R. Otero ◽  
M. Norkin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Efficacy And Safety ◽  
Refractory Multiple Myeloma

Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma

2016 ◽  
Vol 104 (5) ◽  
pp. 596-604 ◽  
Author(s):  
Shinsuke Iida ◽  
Kensei Tobinai ◽  
Masafumi Taniwaki ◽  
Yoshihisa Shumiya ◽  
Toru Nakamura ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase I ◽  
Dose Escalation ◽  
Japanese Patients ◽  
High Dose ◽  
Dose Escalation Study ◽  
Refractory Multiple Myeloma

scholarly journals Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

2019 ◽  
Vol 25 (4) ◽  
pp. 1615-1620 ◽  
Author(s):  
Gergely Varga ◽  
Zsolt Nagy ◽  
Judit Demeter ◽  
Szabolcs Kosztolányi ◽  
Árpád Szomor ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Real World ◽  
Efficacy And Safety ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document